ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
12.56
+0.07 (0.56%)
Mar 31, 2025, 1:13 PM EDT - Market open
ARS Pharmaceuticals Revenue
In the year 2024, ARS Pharmaceuticals had annual revenue of $89.15M with 297,063.33% growth. ARS Pharmaceuticals had revenue of $86.58M in the quarter ending December 31, 2024.
Revenue (ttm)
$89.15M
Revenue Growth
+297,063.33%
P/S Ratio
13.58
Revenue / Employee
$557,181
Employees
160
Market Cap
1.23B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 89.15M | 89.12M | 297,063.33% |
Dec 31, 2023 | 30.00K | -1.29M | -97.72% |
Dec 31, 2022 | 1.32M | -4.19M | -76.10% |
Dec 31, 2021 | 5.51M | -12.33M | -69.13% |
Dec 31, 2020 | 17.84M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SPRY News
- 10 days ago - ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await - Seeking Alpha
- 10 days ago - ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript - Seeking Alpha
- 11 days ago - ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 25 days ago - ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms - GlobeNewsWire
- 27 days ago - ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences - GlobeNewsWire
- 5 weeks ago - ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients - GlobeNewsWire
- 5 weeks ago - ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting - GlobeNewsWire
- 7 weeks ago - ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions - Seeking Alpha